drugset / Trial / NCT03536598

Study to Evaluate the Safety and Efficacy of CJ-30060 in Hypertensive Patients With Hyperlipidemia

NCT03536598

Phase 3 Completed 203 enrolled HK inno.N Corporation
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To evaluate the safety and efficacy of CJ-30060 compared with amlodipine/valsartan combination therapy and valsartan/rosuvastatin combination therapy in hypertensive patients with hyperlipidemia

Timeline

Start
2016-10-14
Primary completion
2017-09-04
Completion
2017-09-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Amlodipine Other / unclassified 10 mg
Comparator Rosuvastatin Small molecule 20 mg
Comparator Valsartan Small molecule 160 mg